Vertex Pharmaceuticals Forecast, price target & analysts
Vertex Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Vertex Pharmaceuticals Classifications & Recommendation
Vertex Pharmaceuticals Price Target
| Target Price | $591.60 |
| Price | $523.93 |
| Potential | 12.92% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target Vertex Pharmaceuticals 2027 . The average Vertex Pharmaceuticals target price is $591.60. This is 12.92% higher than the current stock price. The highest price target is $705.60 34.67% , the lowest is $353.50 32.53% . | |
| A rating was issued by 36 analysts: 29 Analysts recommend Vertex Pharmaceuticals to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2027 of 12.92% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
35 Analysts have issued a sales forecast Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
13 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2026. The average Vertex Pharmaceuticals EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
35 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Vertex Pharmaceuticals net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
35 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Vertex Pharmaceuticals...
Current Vertex Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 08 2026 |
| UBS |
Buy
➜
Buy
|
Unchanged | Sep 28 2026 |
| JP Morgan |
➜
Overweight
|
Unchanged | Sep 11 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Sep 02 2026 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 05 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Aug 05 2026 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Aug 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 08 2026 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Sep 28 2026 |
|
Unchanged
JP Morgan:
➜
Overweight
|
Sep 11 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Sep 02 2026 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 05 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Aug 05 2026 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Aug 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
